As for erythropoietic-stimulating agent therapy, it was suitable only forpatients receiving palliative, myelosuppressive chemotherapy with a Hb <10 g/dLand without absolute iron deficiency [39]. This evidence concerns the gene GSTM1 and nutritional disorder.